$13.62
-0.27 (-1.94%)
Open$14.07
Previous Close$13.89
Day High$14.37
Day Low$13.46
52W High$18.57
52W Low$7.48
Volume—
Avg Volume3.11M
Market Cap2.07B
P/E Ratio—
EPS$-4.64
SectorBiotechnology
Analyst Ratings
Strong Buy
23 analysts
Price Target
+120.7% upside
Current
$13.62
$13.62
Target
$30.06
$30.06
$17.22
$30.06 avg
$35.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 166.56M | 159.79M | 165.80M |
| Net Income | 26.40M | 27.52M | 28.79M |
| Profit Margin | 15.9% | 17.2% | 17.4% |
| EBITDA | 53.49M | 47.96M | 56.14M |
| Free Cash Flow | 17.32M | 22.87M | 17.57M |
| Rev Growth | +0.5% | -2.4% | +23.6% |
| Debt/Equity | 0.62 | 0.47 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |